

CALIXAR to extend its portfolio of strategic compounds for complex pharmaceutical target isolation

PRESS RELEASE - Lyon, France, June 16th 2014

CALIXAR, company specialized in the native isolation of integral membrane protein targets, announced today the issue of a new generation of compounds able to extract and stabilize complex pharmaceutical targets.

Membrane proteins which represent more than 70% of therapeutic targets are known very challenging for biochemists involved in drug or biodrug discovery programs. These biomolecules are very instable outside their biologic membrane and it is very difficult to solubilize and purify them by keeping their structure and all their functionalities. Most of the discovery programs get around this difficulty by working on mutated or truncated forms of the targets that could impact the quality and performance of drugs or biodrugs and consequently cause huge losses for pharmaceutical companies.

"CALIXAR has designed these new compounds with biomimetic approaches. The idea is to translate the biological membrane information into design and synthesis of new compounds that have the ability to keep in solution the functionality and stability of various integral membrane protein targets" said CALIXAR Chief Scientific Officer, Dr Anass JAWHARI.

Dr Emmanuel DEJEAN, CALIXAR Chairman and CEO commented "This innovation has validated a new way for making the best chemistry for the best biochemistry. By implementing these compounds in our isolation strategies for all our discovery programs, our customers will directly take benefits from this. Additionally, we propose specific development of isolation compounds to pharmaceutical companies, in particular for GPCR programs".

About CALIXAR

CALIXAR, based in Lyon (France), offers a unique and patented technological platform allowing to isolate in solution - with the highest purity levels - full-length membrane proteins (GPCRs, Ion Channels, Transporters, Receptors and Viral Proteins), while keeping their structural and functional integrity. CALIXAR's approach represents the opportunity for pharmaceutical companies to start and work with high quality targets or antigens before developing antibodies, formulating vaccines and/or discovering a primary lead through Structure Based Drug Design or High Throughput Screening assays.

For more information, please visit <u>calixar.com</u> or contact Dr Martine MOULY, Chief Communication Officer, <u>mmouly@calixar.com</u>